Psychiatric Bulletin (2008) 32: 53-56. doi: 10.1192/pb.bp.107.015875
© 2008 The Royal College of Psychiatrists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Mahadun, P. N.
Right arrow Articles by Marshall, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Mahadun, P. N.
Right arrow Articles by Marshall, M.

Insight and treatment attitude in schizophrenia: comparison of patients on depot and atypical antipsychotics

P. N. Mahadun

Bolton Salford and Trafford Mental Health NHS Trust, Crisis resolution Home Treatment Team, Chapel Road, Sale, Manchester M33 7EG, email: prem.mahadun{at}trafford.nhs.uk

M. Marshall

School of Psychiatry and Behavioural Sciences, University of Manchester, Preston

Declaration of interest

None.

AIMS AND METHOD

To establish if participants with schizophrenia receiving depot antipsychotics had less insight than similar participants receiving oral atypical antipsychotics. We assessed the difference between these two groups.

RESULTS

Participants on oral antipsychotics had greater insight than those on depot antipsychotics (ITAQ, P=0.01). In the multiple regression analysis, only receiving depot antipsychotics contributed significantly to explaining variance in insight (adjusted R2=0.135, F=8.99, P=0.004).

CLINICAL IMPLICATIONS

Depot antipsychotics seem to be prescribed to a subgroup of people with schizophrenia who are likely to be less adherent because of lower levels of insight. These individuals are on significantly higher doses of antipsychotic medication. Clinicians should review their patients on depot antipsychotics at regular intervals.




This article has been cited by other articles:


Home page
 Br. J. PsychiatryHome page
T. R. E. Barnes, A. Shingleton-Smith, and C. Paton
Antipsychotic long-acting injections: prescribing practice in the UK
The British Journal of Psychiatry, November 1, 2009; 195(52): S37 - S42.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. PsychiatryHome page
L. Waddell and M. Taylor
Attitudes of patients and mental health staff to antipsychotic long-acting injections: systematic review
The British Journal of Psychiatry, November 1, 2009; 195(52): S43 - S50.
[Abstract] [Full Text] [PDF]